Biomarin Pharmaceutical Inc (BMRN)

BMRN (NASDAQ:Drugs)
$81.03
pos +0.00
+0.00%
Today's Range: 75.40 - 81.83 | BMRN Avg Daily Volume: 1,126,500
Last Update: 10/24/14 - 3:59 PM EDT
Volume: 0
YTD Performance: 15.18%
Open: $0.00
Previous Close: $75.01
52 Week Range: $55.04 - $84.25
Oustanding Shares: 147,116,873
Market Cap: 11,035,236,644
6-Month Chart
TheStreet Ratings Grade for BMRN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 11 10 10 10
Moderate Buy 0 0 0 0
Hold 5 5 5 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.63 1.67 1.67 1.67
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -63.03
Price Earnings Comparisons:
BMRN Sector Avg. S&P 500
-63.03 0.00 28.06
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
31.84% 17.50% 144.58%
GROWTH 12 Mo 3 Yr CAGR
Revenue 9.50 0.46 0.13
Net Income 0.00 -1.86 0.00
EPS 0.00 -1.64 0.00
Earnings for BMRN:
EBITDA -0.10B
Revenue 0.55B
Average Earnings Estimates
Qtr (12/14) Qtr (03/15) FY (12/14) FY (12/15)
Average Estimate $-0.62 $-0.49 $-1.32 $-1.15
Number of Analysts 10 1 12 11
High Estimate $-0.45 $-0.49 $-0.96 $-0.71
Low Estimate $-0.73 $-0.49 $-1.97 $-1.80
Prior Year $-0.27 $-0.27 $-0.76 $-1.32
Growth Rate (Year over Year) -128.15% -81.48% -73.79% 12.73%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Robert Moreno

 | Oct 16, 2014 | 1:49 PM EDT

Here are three stock that have returned to former breakout levels.

By

Timothy Collins

 | Sep 29, 2014 | 12:15 PM EDT

Use the oversold bounces for trimming, cutting or hedging positions.

By

Bob Byrne

 | Jul 9, 2014 | 7:30 AM EDT

The focus is on all things momentum.

By

Bob Byrne

 | Jun 23, 2014 | 7:30 AM EDT

For Es, I believe the odds will remain in the bulls' favor.

By

Bob Byrne

 | Jun 19, 2014 | 7:30 AM EDT

No reason to be bearish on the SPY.

By

Bob Byrne

 | Jun 12, 2014 | 7:30 AM EDT

Don't sweat Wednesday's dip in the SPY.

bullishBiomarin upgraded at Credit Suisse

Jun 9, 2014 | 8:20 AM EDT

BMRN was upgraded from Neutral to Outperform, Credit Suisse said. $73 price target. Stock has pulled back to an attractive entry point. 

By

Bob Byrne

 | Jun 5, 2014 | 7:30 AM EDT

The $193 level on the SPY will be key today.

By

Bob Byrne

 | May 29, 2014 | 7:30 AM EDT

Thursday's SPY trade plan will involve fading the edges,

By

Timothy Collins

 | May 19, 2014 | 2:00 PM EDT

BioMarin and Goldcorp couldn't be more different -- and similar.

GS has cleared the important hurdle on the way up which increases the odds for an eventual...
A good quarterly report has sent shares of Calamos Asset Management (CLMS) sharply higher....
Electronics distributor Ingram Micro (IM) reported better than 16% growth in its Q3 sendin...
Market posting decent day considering Ebola getting headlines again. Believe investors ha...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.